These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

835 related items for PubMed ID: 18289713

  • 1. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J, Martínez MA.
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [Abstract] [Full Text] [Related]

  • 2. Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.
    Rezende LF, Prasad VR.
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1716-34. PubMed ID: 15183340
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
    Menéndez-Arias L.
    Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B.
    Virology; 2001 May 10; 283(2):294-305. PubMed ID: 11336554
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.
    Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN.
    J Infect Dis; 2005 Nov 01; 192(9):1537-44. PubMed ID: 16206068
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors.
    Geretti AM.
    AIDS Rev; 2006 Nov 01; 8(4):210-20. PubMed ID: 17219736
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Alcaro S, Alteri C, Artese A, Ceccherini-Silberstein F, Costa G, Ortuso F, Parrotta L, Perno CF, Svicher V.
    Drug Resist Updat; 2011 Jun 01; 14(3):141-9. PubMed ID: 21295512
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Insertions in the beta3-beta4 loop of reverse transcriptase of human immunodeficiency virus type 1 and their mechanism of action, influence on drug susceptibility and viral replication capacity.
    Eggink D, Huigen MC, Boucher CA, Götte M, Nijhuis M.
    Antiviral Res; 2007 Aug 01; 75(2):93-103. PubMed ID: 17416429
    [Abstract] [Full Text] [Related]

  • 20. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
    Zhang M, Han XX, Cui WG, Jia MH, Meng XD, Xing AH, Wu YH, Yang YY, Lu CM, Hu QH, Dai D, Zhang ZN, Shang H.
    Jpn J Infect Dis; 2008 Sep 01; 61(5):361-5. PubMed ID: 18806342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.